159 related articles for article (PubMed ID: 30939349)
1. Structural optimization on a virtual screening hit of smoothened receptor.
Song S; Jiang J; Zhao L; Wang Q; Lu W; Zheng C; Zhang J; Ma H; Tian S; Zheng J; Luo L; Li Y; Yang ZJ; Zhang X
Eur J Med Chem; 2019 Jun; 172():1-15. PubMed ID: 30939349
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.
Lu W; Zhang D; Ma H; Tian S; Zheng J; Wang Q; Luo L; Zhang X
Eur J Med Chem; 2018 Jul; 155():34-48. PubMed ID: 29857275
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
[TBL] [Abstract][Full Text] [Related]
4. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
Zhang H; Sun Z; Liu Z; Song C
Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structure--activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists.
Ma H; Lu W; Sun Z; Luo L; Geng D; Yang Z; Li E; Zheng J; Wang M; Zhang H; Yang S; Zhang X
Eur J Med Chem; 2015 Jan; 89():721-32. PubMed ID: 25462278
[TBL] [Abstract][Full Text] [Related]
6. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
Li QR; Zhao H; Zhang XS; Lang H; Yu K
Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
[TBL] [Abstract][Full Text] [Related]
7. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
[TBL] [Abstract][Full Text] [Related]
8. Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
Shimizu Y; Ishii T; Ogawa K; Sasaki S; Matsui H; Nakayama M
Eur J Pharmacol; 2015 Oct; 764():220-227. PubMed ID: 26048307
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype.
Infante P; Alfonsi R; Ingallina C; Quaglio D; Ghirga F; D'Acquarica I; Bernardi F; Di Magno L; Canettieri G; Screpanti I; Gulino A; Botta B; Mori M; Di Marcotullio L
Cell Death Dis; 2016 Sep; 7(9):e2376. PubMed ID: 27899820
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
Sinha N; Chowdhury S; Sarkar RR
Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
[TBL] [Abstract][Full Text] [Related]
11. A novel hedgehog inhibitor for the treatment of hematological malignancies.
Lin P; He Y; Chen G; Ma H; Zheng J; Zhang Z; Cao B; Zhang H; Zhang X; Mao X
Anticancer Drugs; 2018 Nov; 29(10):995-1003. PubMed ID: 30106753
[TBL] [Abstract][Full Text] [Related]
12. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
[TBL] [Abstract][Full Text] [Related]
13. Identification of Novel Smoothened Ligands Using Structure-Based Docking.
Lacroix C; Fish I; Torosyan H; Parathaman P; Irwin JJ; Shoichet BK; Angers S
PLoS One; 2016; 11(8):e0160365. PubMed ID: 27490099
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
Bhattarai D; Jung JH; Han S; Lee H; Oh SJ; Ko HW; Lee K
Eur J Med Chem; 2017 Jan; 125():1036-1050. PubMed ID: 27810591
[TBL] [Abstract][Full Text] [Related]
15. Design and biological evaluation of phenyl imidazole analogs as hedgehog signaling pathway inhibitors.
Sun C; Zhang Y; Wang H; Yin Z; Wu L; Huang Y; Zhang W; Wang Y; Hu Q
Chem Biol Drug Des; 2021 Mar; 97(3):546-552. PubMed ID: 32946174
[TBL] [Abstract][Full Text] [Related]
16. Vismodegib.
Meiss F; Andrlová H; Zeiser R
Recent Results Cancer Res; 2018; 211():125-139. PubMed ID: 30069764
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
[TBL] [Abstract][Full Text] [Related]
18. Evidence for allosteric interactions of antagonist binding to the smoothened receptor.
Rominger CM; Bee WL; Copeland RA; Davenport EA; Gilmartin A; Gontarek R; Hornberger KR; Kallal LA; Lai Z; Lawrie K; Lu Q; McMillan L; Truong M; Tummino PJ; Turunen B; Will M; Zuercher WJ; Rominger DH
J Pharmacol Exp Ther; 2009 Jun; 329(3):995-1005. PubMed ID: 19304771
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Smo Activity of Some Novel Benzamide Derivatives.
Ding H; Chen K; Song B; Deng C; Li W; Niu L; Bai M; Song H; Zhang L
Molecules; 2017 Dec; 23(1):. PubMed ID: 29301237
[TBL] [Abstract][Full Text] [Related]
20. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
